POLYCYTHEMIA VERA

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study looks at how well the drug ropeginterferon alfa-2b works and is tolerated by people with polycythemia vera, a rare blood cancer that raises red blood cell counts and increases risk of clots. Researchers will follow 319 patients in Italy to see if the drug helps control…

This study tests a combination of three drugs (azacitidine, venetoclax, and pevonedistat) in adults with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that is either related to prior cancer treatment or developed from other blood disorders. The goal is to fin…

This study tested whether adding the drug veliparib to standard chemotherapy helps people with advanced blood cancers like acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). About 25 adults took part. The goal was to see if the combination improved response …

This study tests an experimental drug called SLN124 in 69 adults with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to see if SLN124 can safely reduce the need for phlebotomies (blood removal) and help control blood counts. The trial ha…

This study tests a drug called IMG-7289 in people with two rare blood cancers—essential thrombocythemia (ET) and polycythemia vera (PV)—that did not get better with standard treatments. The goal is to see if the drug can help control blood cell counts and reduce symptoms. The tri…

This study checks the long-term safety of the drug ruxolitinib (given alone or with panobinostat) in people with certain blood or immune conditions like myelofibrosis, polycythemia vera, graft-versus-host disease, acute myeloid leukemia, or thalassemia. Participants had already b…

This program gives eligible patients with polycythemia vera (a rare blood cancer causing too many red blood cells) access to the drug ruxolitinib. It is for people aged 12 and older who cannot take or have stopped responding to standard treatments like hydroxyurea. The goal is to…

This study watches 242 people with high-risk polycythemia vera, a blood condition that raises the risk of dangerous blood clots. Researchers track things like blood pressure, weight, and lab tests to see which factors best predict clots. The goal is to help doctors identify who i…